Firefly BioWorks, Inc. Announces the Award of a $2M Grant from the National Institutes of Health for microRNA Profiling in

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Firefly BioWorks, Inc., a manufacturer of universally compatible multiplex assays, announced today it was awarded a $2M Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute for microRNA profiling. MicroRNAs are an emerging class of biomarkers that are proving to be important indicators for early diagnosis of cancer and other diseases. The company will use the award to expand production capacity and validate its microRNA assay against the current state of the art. The goal of the Phase II studies is to develop a product providing a combination of performance, throughput and cost not available from existing solutions.

"We are excited to build upon promising results from Phase I," said Dr. Daniel Pregibon, Firefly co-founder and CTO, "and look forward to working with our academic and industry partners to develop innovative research tools in this important field." Firefly's core technology was developed in the laboratory of Prof. Patrick Doyle, in the Chemical Engineering Department at MIT, who said: "I am very excited to see an academic discovery from my lab being translated into a product which holds great promise for improving cancer research and diagnosis." Prof. Doyle is also a Firefly co-founder and chairs its Scientific Advisory Board.

"We are extremely grateful to the Small Business Innovation Research program and the National Cancer Institute for their continued support of our technology and vision," said Dr. Davide Marini, Firefly co-founder and CEO. "The SBIR program continues to provide a crucial source of energy to the entrepreneurial ecosystem, which is at the heart of America's competitiveness."

About Firefly BioWorks

Firefly BioWorks, Inc. (Cambridge, MA) is introducing an open platform allowing industrial, academic and clinical scientists to develop and use multiplexed biological assays on standard laboratory instrumentation. The company's first line of products will consist of encoded hydrogel microparticles that can be read on standard flow cytometers, microarray readers and fluorescence microscopes. Firefly's multi-functional microparticles are produced by Optical Liquid Stamping, a ground-breaking microfabrication method allowing rapid synthesis of complex reagents for biological analysis. The company's long-term vision is to provide research and clinical scientists with reliable and affordable solutions for the comprehensive characterization of biological function.



CONTACT:

Firefly BioWorks, Inc.
Davide Marini, 617-500-6247
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Oncology

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.